Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Gains from Investment Securities (2020 - 2026)

Climb Bio filings provide 7 years of Gains from Investment Securities readings, the most recent being $152530.0 for Q1 2026.

  • Quarterly Gains from Investment Securities rose 1425.3% to $152530.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $152530.0 through Mar 2026, down 97.63% year-over-year, with the annual reading at $6.4 million for FY2025, 128.12% up from the prior year.
  • Gains from Investment Securities hit $152530.0 in Q1 2026 for Climb Bio, down from $1.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.4 million in Q4 2024 and bottomed at $10000.0 in Q1 2025.
  • Average Gains from Investment Securities over 5 years is $2.1 million, with a median of $1.4 million recorded in 2025.
  • The largest annual shift saw Gains from Investment Securities tumbled 98.9% in 2023 before it surged 3528.1% in 2024.
  • Climb Bio's Gains from Investment Securities stood at $4.5 million in 2022, then tumbled by 98.9% to $50000.0 in 2023, then skyrocketed by 12730.0% to $6.4 million in 2024, then tumbled by 79.77% to $1.3 million in 2025, then tumbled by 88.25% to $152530.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Gains from Investment Securities are $152530.0 (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q2 2025).